0000899243-20-032941.txt : 20201207
0000899243-20-032941.hdr.sgml : 20201207
20201207215044
ACCESSION NUMBER: 0000899243-20-032941
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201203
FILED AS OF DATE: 20201207
DATE AS OF CHANGE: 20201207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harding Thomas C.
CENTRAL INDEX KEY: 0001834833
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 201374276
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-12-03
0
0001466301
Clovis Oncology, Inc.
CLVS
0001834833
Harding Thomas C.
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
3210
D
Stock Option (right to buy)
73.98
2024-01-10
Common Stock
2167
D
Stock Option (right to buy)
78.38
2024-02-27
Common Stock
30000
D
Stock Option (right to buy)
79.05
2025-03-02
Common Stock
9350
D
Stock Option (right to buy)
85.88
2025-07-01
Common Stock
20000
D
Stock Option (right to buy)
22.73
2026-08-25
Common Stock
21047
D
Stock Option (right to buy)
59.27
2027-03-01
Common Stock
4250
D
Stock Option (right to buy)
58.43
2028-03-01
Common Stock
4500
D
Stock Option (right to buy)
3.40
2029-10-30
Common Stock
35000
D
Restricted Stock Units
2027-03-01
Common Stock
516
D
Restricted Stock Units
2028-03-01
Common Stock
1688
D
Restricted Stock Units
2029-02-01
Common Stock
14063
D
Restricted Stock Units
2030-01-31
Common Stock
29000
D
On January 10, 2014, the reporting person was granted 8,000 options. The options are fully vested and are immediately exercisable.
On February 27, 2014, the reporting person was granted 30,000 options. The options are fully vested and are immediately exercisable.
On March 2, 2015, the reporting person was granted 9,350 options. The options are fully vested and are immediately exercisable.
On July 1, 2015, the reporting person was granted 20,000 options. The options are fully vested and are immediately exercisable.
On August 25, 2016, the reporting person was granted 33,675 options. The options are fully vested and are immediately exercisable.
On March 1, 2017, the reporting person was granted 4,250 options. The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
On March 1, 2018, the reporting person was granted 4,500 options. The option vested as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
On October 30, 2019, the reporting person was granted 35,000 options. The option vests as to 25% of the shares on October 30, 2020, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
On March 1, 2017, the reporting person was granted 4,125 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On March 1, 2018, the reporting person was granted 4,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vest on January 31, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Senior Vice President and Chief Scientific Officer
/s/ Thomas C. Harding
2020-12-07